Search Results

Bleomycin Sulfate 50 mg  | Purity Not Available

TargetMol

Bleomycin Sulfate, a glycopeptide antibiotic, is an anticancer agent for squamous cell carcinomas (SCC). In UT-SCC-19A cells, the IC50 of Bleomycin Sulfate is 4 nM.

More Information Supplier Page

Bleomycin Sulfate 5 mg  | Purity Not Available

TargetMol

Bleomycin Sulfate, a glycopeptide antibiotic, is an anticancer agent for squamous cell carcinomas (SCC). In UT-SCC-19A cells, the IC50 of Bleomycin Sulfate is 4 nM.

More Information Supplier Page

Bleomycin Sulfate 2 mg  | Purity Not Available

TargetMol

Bleomycin Sulfate, a glycopeptide antibiotic, is an anticancer agent for squamous cell carcinomas (SCC). In UT-SCC-19A cells, the IC50 of Bleomycin Sulfate is 4 nM.

More Information Supplier Page

Bleomycin Sulfate 100 mg  | Purity Not Available

TargetMol

Bleomycin Sulfate, a glycopeptide antibiotic, is an anticancer agent for squamous cell carcinomas (SCC). In UT-SCC-19A cells, the IC50 of Bleomycin Sulfate is 4 nM.

More Information Supplier Page

Palmitoylethanolamide 200 mg  | 100.00%

TargetMol

Palmitoylethanolamide is an endogenously fatty acid amide. It has a role as an anti-inflammatory drug, an antihypertensive agent, a neuroprotective agent and an anticonvulsant.Upon administration, palmitoylethanolamide may inhibit the release of pro-inflammatory mediators from activated mast cells.

More Information Supplier Page

Palmitoylethanolamide 25 mg  | 100.00%

TargetMol

Palmitoylethanolamide is an endogenously fatty acid amide. It has a role as an anti-inflammatory drug, an antihypertensive agent, a neuroprotective agent and an anticonvulsant.Upon administration, palmitoylethanolamide may inhibit the release of pro-inflammatory mediators from activated mast cells.

More Information Supplier Page

Palmitoylethanolamide 10 mg  | 100.00%

TargetMol

Palmitoylethanolamide is an endogenously fatty acid amide. It has a role as an anti-inflammatory drug, an antihypertensive agent, a neuroprotective agent and an anticonvulsant.Upon administration, palmitoylethanolamide may inhibit the release of pro-inflammatory mediators from activated mast cells.

More Information Supplier Page